TP63
Overview
TP63 (Tumor Protein P63) encodes a member of the p53 family of transcription factors that is a master regulator of squamous epithelial differentiation. Unlike TP53, TP63 acts as an oncogene in squamous cell carcinomas through genomic amplification at 3q26-29, a locus co-amplified with SOX2. TP63 (particularly the DeltaNp63 isoform) promotes squamous cell survival and stemness.
Alterations observed in the corpus
- TP63 and SOX2 are co-amplified at 3q in 48% of ESCCs (ESCC) in the TCGA esophageal carcinoma cohort (stes_tcga_pub, n=90 ESCC); combined amplification is higher in the ESCC1 molecular subtype (classical squamous / NRF2-pathway subtype). PMID:28052061
- Discriminating regulon between miRNA clusters within the basal/squamous MIBC mRNA subtype (activated in miR-4, repressed in miR-2) PMID:28988769
Cancer types (linked)
- ESCC: TP63 amplification at 3q (combined with SOX2) is one of the most prevalent copy-number events in ESCC; defines squamous lineage identity. Enriched in ESCC1. The authors propose Hippo/YAP1-targeted approaches for SOX2/TP63-amplified ESCC1 tumors. PMID:28052061
Co-occurrence and mutual exclusivity
- Co-amplified with SOX2 at the 3q amplicon in ESCC; this co-amplification is a defining feature of the squamous-lineage transcriptional program. PMID:28052061
Therapeutic relevance
- SOX2/TP63-amplified ESCC1 tumors with Hippo pathway activation are proposed candidates for Hippo/YAP1-targeted therapy. PMID:28052061
Open questions
- Prospective clinical evidence for TP63 amplification as a predictive biomarker for Hippo-pathway inhibitors in ESCC is lacking in the corpus. PMID:28052061
Sources
This page was processed by entity-page-writer on 2026-05-15. - PMID:28988769
This page was processed by wiki-cli on 2026-05-15.